online | memorias.ioc.fiocruz.br Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 107 (7): 846-853, November 2012 Rotavirus infection remains a major cause of severe diarrhoeal disease in young children worldwide and accounts for approximately 2.4 million hospitalisations and > 450,000 deaths each year (Parashar et al. 2009 , WHO 2009 , Tate et al. 2012 . It is estimated that 85% of these deaths occur in developing countries. The highest mortality rates are in low-income areas of Asia and sub-Saharan Africa, where access to medical care is very limited and risk factors for rotavirus infection are significant. According to a recent study in 14 Latin American countries, the burden of disease attributable to rotavirus, in the absence of rotavirus vaccination, has been estimated at 229,656 hospitalisations and 6,302 deaths annually among children younger than five years of age (Desai et al. 2012) .
Rotavirus strains are mainly classified by a dual nomenclature system according to two surface proteins, namely VP4 (a protease-sensitive protein) and VP7 (a glycoprotein), defining the P and G protein types, respectively. Currently, 35 P-types and 27 G-types have been reported in mammalian and avian species. Of these, 15 P-types and 12 G-types have been identified in human infections (Matthijnssens et al. 2011 (Santos & Hoshino 2005) . Significantly, strains that have G9 combined with either P [8] or P[6] VP4 specificity are currently recognised as one of the globally emerging rotavirus types.
Since 2006, the following two human, live-attenuated oral vaccines have been licensed and are commercially available: a human-bovine pentavalent reassortant rotavirus vaccine (RV) (RotaTeq™; Merck & Co) and a monovalent vaccine composed of a human G1P [8] rotavirus strain (Rotarix™; GlaxoSmithKline Biologicals). Data from large, pivotal clinical trials that included both vaccines and were conducted in Latin America, the United States and Europe yielded results demonstrating a highly protective efficacy against severe rotavirus gastroenteritis. The results also demonstrated a safety profile that indicated a lower risk of intussusception than that previously reported for Rotashield TM (O'Ryan & Linhares 2009 ). Of particular importance were the results from two Phase III trials recently completed. In a study performed in South Africa and Malawi (Rotarix TM ) and another study performed in Kenya, Ghana, Mali, Bangladesh and Vietnam (Rotateq  TM ) , an overall lower, though significant, performance was noted compared with that in the pivotal studies (Armah et al. 2010 , Madhi et al. 2010 , Zaman et al. 2010 . A two-dose schedule of Rotarix TM , for instance, yielded protective efficacy rates of 72% [95% confidence interval (CI) 40-88%] and 49% (95% CI 11-72%) in South Africa and Malawi, respectively (Madhi et al. 2010) . In light of data from the clinical trials conducted to date, rotavirus vaccination is largely recognised as the most effective public health strategy for the prevention of rotavirus disease and vaccination is believed to have (Linhares et al. 2008 ). In addition to providing protection against individual G1, G3, G4 and G9 types, efficacy was also significant against pooled non-G1 (G3, G4 and G9) rotavirus serotypes [80% (95% CI: 67.9-88.8%)]. A trend for protection against G2P[4] strains was also observed.
Since 2006, 12 countries in Latin America have incorporated Rotarix TM into their national immunisation programs and its positive efficacy under "real conditions" has been demonstrated in recent efficacy studies conducted in Brazil, El Salvador and Panama (Gurgel et al. 2009 , Correia et al. 2010 , de Palma et al. 2010 , Justino et al. 2011 , Molto et al. 2011 ). In addition, vaccination impact studies have demonstrated that Rotarix TM is likely to have had a major influence in the decrease in rates of morbidity and mortality in Brazil and Mexico during the post-introduction period (Lanzieri et al. 2010 , Richardson et al. 2010 , do Carmo et al. 2011 .
Although pivotal clinical trials and post-licensure studies with currently available rotavirus vaccines have clearly documented their effectiveness in protecting against severe rotavirus gastroenteritis, it seems crucial to continue the surveillance of rotavirus disease burden and circulating strains. This surveillance is particularly important in developing countries in which the great diversity of co-circulating rotavirus serotypes, with possible emergence of either reassortant or even potential zoonotic strains, may be potentially challenging for current vaccine strategies (Santos & Hoshino 2005 , Matthijnssens et al. 2009 ).
This paper focuses on the efficacy of Rotarix TM in Belém, northern Brazil, one of the 11 settings in Latin America where a major Phase III study was conducted between 2003-2005 to evaluate both the safety and efficacy of this vaccine (Ruiz-Palacios et al. 2006 , Linhares et al. 2008 . Because G9 rotavirus was the predominant serotype in Belém throughout the study period, we were able to provide further evidence of significant, sustained protection during the first two years of life against severe rotavirus gastroenteritis caused by this globally emergent strain and the VP-7 serotypically unrelated strain.
PATIENTS, MATERIALS AND METHODS
The safety and efficacy of Rotarix TM were originally assessed in a large, randomised, double-blind Phase III trial in 11 Latin American countries between August 2003-October 2005. The trial included over 63,000 healthy infants who were followed until they were one year old (Ruiz-Palacios et al. 2006) . Of these infants, an efficacy subset cohort of approximately 15,000 infants from 10 Latin American countries was followed up to the age of two years. This follow-up study included the area of Belém (Linhares et al. 2008) where 653 healthy infants were recruited to assess vaccine efficacy up to the second year of life. Inclusion and exclusion criteria were described in detail in a previous publication (RuizPalacios et al. 2006) . Study approvals were granted by the Institutional Ethical Review Committee and the National Ethical Review Board. The trial was carried out in compliance with the October 1996 version of the Helsinki Declaration and the Good Clinical Practices guidelines. Written informed consent was obtained from parents or legal guardians prior to the enrolment of the 653 infants in Belém. Most of the study participants were from low-income families living in the outskirts of Belém, where generally poor sanitation conditions exist. The eligible subjects were healthy full-term infants between six-13 weeks of age. They were randomly assigned in a 1:1 ratio to receive two doses of either Rotarix TM (RIX4414 strain) or placebo. Vaccine and placebo compositions are provided in detail elsewhere (Ruiz-Palacios et al. 2006 , Linhares et al. 2008 . Of note, treatment allocation was concealed from the investigators and the parents/legal guardians of participating infants throughout the entire study period. Two oral doses of Rotarix TM or placebo were administered to 328 and 325 healthy infants in Belém, respectively, at approximately two and four months of age. All enrolled infants received other routine childhood immunisations in compliance with the official national schedule. Oral poliovirus vaccine was given at least two weeks before or after the administration of Rotarix TM or placebo. A hospital-based surveillance for severe gastroenteritis of any cause was conducted in Belém during the follow-up period, as described previously (Ruiz-Palacios et al. 2006) . In Belém, trained field workers made daily visits to 24 hospitals and 26 official health care units across the city to identify cases of severe gastroenteritis among the enrolled subjects. Cases of severe gastroenteritis were defined as an episode of diarrhoea (the passage of 3 or more looser-than-normal or watery stools within a 24-h period), with or without vomiting, requiring an overnight hospitalisation or rehydration treatment according to the WHO's plan B (oral rehydration therapy) or plan C (intravenous fluid therapy). The severity of gastroenteritis was assessed using the 20-point Vesikari scoring system, where episodes graded ≥ 11 were considered to be severe (Ruuska & Vesikari 1990 ).
The stool samples were collected from children within 48 h after being hospitalised or at any health unit where they received rehydration therapy. Specimens were stored at 2-8ºC before daily transfer to the Evandro Chagas Institute, Belém, a Ministry of Health's National Rotavirus Reference Laboratory, and frozen at -20ºC until processing. Stool samples were analysed locally (and further retested at the laboratories of GlaxoSmithKline Biologicals in Rixensart, Belgium) to detect rotavirus antigen by means of an enzyme-linked immunobosorbent assay (Rotaclone, Meridian Bioscience, Cincinatti, OH, USA). Rotavirus-positive stool samples were tested using reverse transcriptase-polymerase chain reaction of the VP7 and VP4 genes, followed by reverse hybridisation and (optional) sequencing at DDL Diagnostic Laboratory (Voorburg, The Netherlands) to identify G and P genotypes and to differentiate between the presence of wild-type G1 rotavirus and the vaccine strain virus. The data analysis was performed at GlaxoSmithKline Biologicals, Rixensart, Belgium, using SAS software (version 8.2, SAS Institute Inc, Cary, NC, US) and Proc StatXact 5 on Windows NT (version 4.0) and was described in detail previously (Ruiz-Palacios et al. 2006 , Linhares et al. 2008 . In brief, the Belém cohort consisted of subjects who completed the full two-dose vaccination course and were followed up from two weeks after dose 2 until approximately 24 months of age. An original sample size [10 Latin American countries (Linhares et al. 2008 )] of 5,600 children per group (vaccine and placebo) was estimated (similar numbers for each country were planned). This estimate was determined by assuming a 60% efficacy in the second year efficacy follow-up and an incidence rate of 1% for severe rotavirus gastroenteritis to achieve at least 90% power for the study and a 95% CI for the vaccine efficacy that would be above 0%. In Belém, the overall assumed incidence of rotavirus-related severe gastroenteritis in the placebo group is comparable to that reported elsewhere in Brazil. The vaccine and placebo groups were compared in terms of incidence rate with a two-sided Fisher's exact test (α = 0.05) and vaccine efficacy was calculated with the associated 95% CI computed using the formula (1-relative risk) x 100.
RESULTS
In Belém, a total of 653 infants were enrolled in the study, 630 of whom completed the two-year follow-up to assess vaccine efficacy. There were 23 infants who dropped out of the study because they were unable to attend the final visit of the follow-up period for the following reasons: 11 moved outside the study area, the parents of seven children withdrew consent and five died of vaccine-unrelated causes (Fig. 1) . Vaccine and placebo cohorts were shown to be comparable with respect to demographic characteristics that included mean ages at the time of the first and second doses, gender distribution and race or ethnic background. The number of children who completed the two-year efficacy surveillance period was also similar for both the vaccine (n = 319) and the placebo (n = 311) cohorts (Table I) . a: number in parentheses, range; b: "mixed" or mestizo. Table II summarises the features of rotavirus gastroenteritis episodes (RGE) reported in both the vaccine and placebo cohorts during the two-year efficacy surveillance period. Overall, there were 37 RGE distributed among the vaccine (n = 9) and placebo (n = 28) groups, 36 (97.3%) of which were rated as severe according to the Vesikari scale (Ruuska & Vesikari 1990 ). Most (30/37; 81%) of the rotavirus gastroenteritis cases were detected during the second year of follow-up, including 23 (76.7%) episodes that were classified as severe in the placebo cohort. Taking both efficacy surveillance periods together, 78 serotype specificities were defined, including 16 and 52 individual G and P-types in the first and second years of follow-up, respectively. The predominant types were wild-type G1 (n = 22; 28%), G9 (19; 24%) and P[8] (37; 47.4%). Fig. 2 shows the frequencies of rotavirus serotypes in the placebo group in each year of follow-up based on the dual (G and P) nomenclature system. During the first year of surveillance, G9P [8] was the predominant strain, accounting for 60% of the five G and P-typed strains identified, followed by G1P [8] Table III presents the vaccine protective efficacy data for severe RGE according to the protocol cohort. The frequency of RGE requiring hospital admission or rehydration therapy (WHO plan B or C) was much lower in the first efficacy follow-up period than in the second efficacy follow-up period [7/617 (1.1%) and 29/609 (4.8%), respectively; p = 0.0001]. Combining the first and second efficacy follow-up periods, eight (2.6%) of the 309 children allocated to the vaccine group vs. 28 (9.3%) of the 300 children assigned to the placebo group developed severe rotavirus gastroenteritis, yielding a vaccine efficacy of 72.3% (95% CI 37.5-89.1; p = 0.0005). The vaccine efficacy against severe rotavirus gastroenteritis was 60.6% (95% CI 140.4-96.3; p = 0.283) in the firstyear efficacy period and 74.7% (95% CI 36.0-91.6; p = 0.001) in the second-year efficacy period. (40) 7 (100) 0 (0) 1 (14.3) 6 (85.7) 15 (100) 7 (46.7) 1 (6.7) 7 (46.7) 9 (100) 0 (0) 1 (11.1) 8 (88.9) 20 (100) 8 (40) 3 (15) 9 (45) 5 (100) 0 (0) 0 (0) 5 (100) 11 (100) (100) 47 (100) 12 (25.5) 12 (25.5) 23 (48.9) 28 (100) 0 (0) 0 (0) 28 (100) 58 (100) 14 (24.1) 16 (27.6) 28 (48.3) a: RGE episodes reported from two weeks after dose 2 up to visit 4; b: severity according to the 20-point Vesikari scale; c: RGE episodes reported from visit 4 to visit 6; d: RGE episodes reported from two weeks after dose 2 up to visit 6; RV: rotavirus vaccine. 
DISCUSSION
Our study findings indicated that two oral doses of Rotarix TM provided a sustained significant protection against severe rotavirus gastroenteritis among children living in Belém during their first two years of life. Of special importance in this study was the good efficacy against G9 rotavirus, a G type currently recognised as a globally emerging strain reported at remarkably increasing frequency worldwide over the past 10 years (Santos & Hoshino 2005 ). Also of importance is the fact that G9 rotaviruses are representative of non-G1 strains, which do not have the same VP7 type specificity as the vaccine strain.
Unlike several other Rotarix TM trials, the large predominance of the G9P[8] serotype in Belém during the first (60% of strains) and second (48% of strains) years of follow-up provided a unique opportunity to assess the performance of the vaccine in a setting where a heterotypic rotavirus strain was predominant. In Belém, as in the locations of most Rotarix TM efficacy studies all over the world (de Vos et al. 2009), G1P[8] strains were also circulating at high frequencies during the first (20%) of strains and second (48%) years of efficacy surveillance.
Overall, the levels of protection against severe rotavirus gastroenteritis (score ≥ 11 on the Vesikari scoring system) in Belém were similar when comparing the second year of follow-up with the combined two-year follow-up period: 74.7% (95% CI 36.0-91.6; p = 0.001) and 72.3% (95% CI 37.5-89.1; p = 0.0005), respectively. Although vaccination also resulted in an approximately 61% reduction in the incidence of severe rotavirus gastroenteritis during the first year of life, the results were not statistically significant because of the low number of subjects reporting rotavirus illness. The protective efficacy rates in Belém for the second efficacy period and for the two periods combined were similar to those found in a large Phase III trial in Latin America (including Belém as one of the study settings), where the vaccine was 79% (95% CI 66.4-87.4) and 80.5% (95% CI 71.3-87.1) protective in the second efficacy period and the combined two-year efficacy period, respectively (Linhares et al. 2008) . Also in accordance with a previously reported vaccine performance in Latin America, the overall level of protection in Belém was lower than that obtained in clinical trials conducted in Europe, where Rotarix TM conferred a 90% (95% CI 85-94) protection against severe rotavirus gastroenteritis disease during two consecutive rotavirus seasons (Vesikari et al. 2007 , O'Ryan & Linhares 2009 ). Although statistically significant efficacy data were not available for Belém in the first year of follow-up, due to the small number of cases, it seems likely that the protection rate would be similar to that obtained recently in South 3)] but higher than that in Malawi [49.2% (95% CI (11.1-71.7)] (Madhi et al. 2010) .
Rotavirus type G9P [8] was the predominant strain circulating during the first efficacy follow-up period in Belém, accounting for 60% of cases. In the second year of this study, there was a large increase in the proportion of wild-type G1P [8] , reaching a prevalence rate (approximately 48%) similar to that of G9P [8] . Of interest, this changing pattern of rotavirus strains during the two-year follow-up period appears to differ from that observed for Latin America as a whole, where a shift in type predominance was noted as follows: G1P[8] wild-type rotavirus was the most common strain (52% of strains) found during the first rotavirus season, whereas G9P[8] gained predominance (54%) during the second year of the efficacy follow-up period (Linhares et al. 2008) . These contrasting findings highlight the fact that changes may occur quickly over time and that different rotavirus strains can become predominant in different geographical locations at the same time (O'Ryan & Linhares 2009 ).
Several pre-licensure studies have demonstrated the efficacy of Rotarix TM against severe rotavirus gastroenteritis caused by the common rotavirus, which bears G1, G3, G4, G9 and P[8] type specificities (Salinas et a: RGE episodes reported from two weeks after dose 2 up to visit 4; b: RGE episodes reported from visit 4 up to visit 6; c: RGE episodes reported from two weeks after dose 2 up to visit 6; n: number of subjects reporting at least one severe RGE episode in each group. , Ruiz-Palacios et al. 2006 , Vesikari et al. 2007 , O'Ryan & Linhares 2009 ). This finding was corroborated using an integrated analysis of vaccine efficacy, showing that Rotarix TM confers broad protection against gastroenteritis caused by circulating rotavirus strains with and without the VP7 and VP4 type specificities shared with those of the vaccine strain, including the full heterotypic G2P[4] serotype (de Vos et al. 2009 ).
The fact that such a single-strain (G1P[8] ) RV can afford cross-protection early in infancy also became evident in recent, post-vaccine introduction studies performed to assess efficacy "under real conditions" (Snelling et al. 2009 , Correia et al. 2010 , Justino et al. 2011 .
The large predominance of the G9P[8] serotype during the first and second years of the efficacy follow-up for period (60% and 48%, respectively) makes our study in Belém unique compared with other Rotarix TM trials, in which most of the isolates belonged to the G1 serotype (O'Ryan & Linhares 2009 ). It is of major importance in this context to highlight that the number of countries reporting G9 strains has increased remarkably during the past 10 years, suggesting that it is a globally emerging serotype (Gentsch et al. 2005 , Santos & Hoshino 2005 . Notably, studies conducted in Belém and elsewhere have suggested that the G9 serotype appears to be associated with a greater disease severity, particularly with regard to the need for rehydration treatment (Cubbit et al. 2000 , Linhares et al. 2006 . Furthermore, in late 2005, rotavirus genotype G9 was associated with an extensive outbreak of acute gastroenteritis in Rio Branco, state of Acre, in the western Amazon area of Brazil. The outbreak affected more than 20% of children younger than five years old (Siqueira et al. 2010 ) and caused many deaths.
In a previous Phase II trial conducted in Belém, that followed children until one year of age, Rotarix TM was found to be highly efficacious 3)] against G9 strains of rotavirus (Salinas et al. 2005 , Araujo et al. 2007 ). Of importance is the fact that the results of the present study add evidence to support previous findings that high protection against severe rotavirus gastroenteritis, caused by the emerging G9 serotype, is sustained during the first two years of life [82% (95% CI 38-95)], which is when the disease burden is highest in our region (Linhares et al. 1996) .
Although the large studies involving 11 Latin American countries (including Belém, Brazil) (Ruiz-Palacios et al. 2006 , Linhares et al. 2008 were not originally powered to assess vaccine efficacy for every individual setting, the results from our current post-hoc analysis clearly demonstrate a significant protection against severe rotavirus gastroenteritis caused by G9 strains during the first two years of life. An additional limitation of our analysis is that protection against serotypes G1 and G9 could not be assessed for the first year of life due to the small number of cases.
The results of this Brazilian subset of the Phase III trial in Belém strengthen those results from previ- a: RGE episodes reported from two weeks after dose 2 up to visit 4; b: RGE episodes reported from visit 4 up to visit 6; c: RGE episodes reported from two weeks after dose 2 up to visit 6; n: number of subjects reporting at least one severe RGE episode in each group. ous studies performed in Latin America and elsewhere, showing that two oral doses of Rotarix TM given early in infancy provide a sustained level of high protection against severe rotavirus gastroenteritis during the first two years of life (O'Ryan & Linhares 2009 ). This result is of particular importance considering that the local study was conducted in a setting that clearly reflects the low socio-economic conditions and high diarrhoeal disease incidence typical of developing countries. In conclusion, our study findings demonstrate significant heterotypic rotavirus protection against the globally emerging G9 strain. The protection is sustained for up to two years of age, when the disease burden is highest. Nonetheless, with the increasing worldwide adoption of rotavirus vaccines in national immunisation programs, it is crucial to closely monitor long-term trends of viral serotypes. This monitoring would allow for the assessment of any impact of vaccination on circulating rotaviruses and would also allow for the identification of possible newly emerging strains that may evade immunity to rotavirus vaccines.
